Formulation and evaluation of simvastatin floating tablets

YADUBANSH GUPTA, ISHRAT ALIM* and DABEER AHMAD

Department of Pharmacy, Singhania University, Jhunjhunu (Rajasthan).
*Quality Assurance Laboratory, M.P. Council of Science and Technology,
Vigyan Bhavan, Science Hills, Nehru Nagar, Bhopal (India).

(Received: April 12, 2010; Accepted: June 04, 2010)

ABSTRACT

In the present study we report, the various processing parameters and formulations aspects for developing a pharmaceutical equivalent, stable, cost improved and quality improved formulation of floating tablet of Simvastatin comparable with innovator and optimize certain process parameters to get maximum yield of the product during large scale manufacturing. Being a Class II drug, Simvastatin shows slow dissolution rate, limited oral absorption and high variability in pharmacological effects. Present study has been done for improving the absorption and its bioavailability in order to establish controlled floating drug delivery systems of Simvastatin. Four formulations were prepared by using of HPMC K4M and Ethyl cellulose as polymers and fixed amount of gas generating agent sodium bicarbonate and hydrophobic material bees wax by melt granulation technique and it was noticed that the prepared tablets constantly found to be buoyant for more than 8 hours in the released medium. In vitro drug release, kinetic data and related stability studies after optimization of promising formulation of selected drug are being done to exhibit diffusion dominant drug release and its stability may be attributed to that the present problem certainly will be helpful and surely will open an avenue for new trend of control drug delivery system.

Key words: Oral drug delivery system, sustained release of drug, Simvastatin Floating tablets, Buoyancy.

INTRODUCTION

Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in human or animals and may be delivered in many different ways using many different delivery systems. There are many physiological limitations because of incomplete drug release from the oral drug release system causes incomplete drug absorption and very short G1 transit time of the dosage forms1,2. The history of controlled drug delivery technologies spans over five decades for the introduction of controlled-release delivery system. Oral drug delivery systems are gaining popularity and acceptance as technologies evolve. Together with easy administration, they also offer innovative solutions for some key challenges faced by the Biopharma Industry. Advances made in controlled drug delivery, especially over the past two decades, have been significant. During the period, several attempts have been made for designing many drug delivery systems and for different formulations that control the rate and period of drug delivery i.e., time-release medications and target specific areas of the body for treatment have become increasingly common and complex to overcome physiological limitations3,5. Floating drug delivery system is now the best low density system that has sufficient buoyancy to float over the gastric content and remain in the stomach for a prolonged period, and release the drug slowly at desired rate in controlled manner. Hydro dynamically balanced system under single and multiple unit dosage forms have been developed for reliable formulations5,7.

Simvastatin, a crystalline compound, and is practically insoluble in water and hence poorly absorbed from the G1 tract. It is a potent and
specific inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG COA) reductase, which catalyzes the reduction of HMG COA to mevalonate. Thus Simvastatin arrests a key step for cholesterol biosynthesis in liver, and is hence, widely used in the treatment of hypercholesterolemia and dyslipidemia as an adjunct to diet. The Tablet of Simvastatin is already in market since a long time. In current International scenario it is very difficult to launch a new molecular entity as it involves a lot of money expenditure and time. Therefore the reduction in cost of manufacturing processes and production of existing product lured many industries to optimize the processes to get maximum output. In the present investigation floating tablets of Simvastatin were prepared containing varying proportions of HPMC K4M and Ethyl cellulose as polymers to improve the absorption and its oral bioavailability.

MATERIAL AND METHODS

Simvastatin pure drug and HPMCK4M was received as a gift from LUPIN Private Ltd. Pune. Ethyl cellulose, Sodium bi carbonate, Bee wax, Magnesium Stearate, and Talk and other chemicals and reagents were procured from E. Merck (India) Ltd., Mumbai. All the chemicals were of laboratory grade and used as such without any further purification.

Pre formulation characterization of the pure drug was performed for comparing the data with different developed formulations (F-1 to F-4), obtained from the analysis of formulation of Simvastatin. Physical Description done as general appearance of the drug, its visual identity and overall ‘elegance’ is essential, this parameter was done and it was noticed by observing the colour of the drug simply, the solubility of the drug with the standard descriptive term with solvent series was checked, Similarly melting point of the pure drug was considered for the temperature at which the vapor pressure of the drug and the liquid were found equal and exists in equilibrium. Partition- (P) or distribution coefficient (D) was noted as the ratio of concentration of a compound in the two phases of a mixture of two immiscible solvents at equilibrium, and accordingly, the coefficients was measured for differential solubility of the compound between these two solvents. The Loss on Drying Test was accomplished at 60°C to measure the amount of water and volatile matters in a drug when the drug was dried under specified conditions.

Preparation of Floating Tablets by Melt granulation technique

Four formulations containing varying properties of polymers like HPMC K4M and Ethyl cellulose and fixed amount of gas generating agent i.e. Sodium bicarbonate and hydrophobic meltable material like Bee wax were prepared as per the composition expressed in the Table – 1. Required quantity of bee wax was weighed and melted in a large china dish over water bath. The weighed drug was added to the molten wax and mixed well. Previously weighed quantities of HPMC K4M, Ethyl cellulose and Sodium bi carbonate was added to the drug-wax mixture and mixed thoroughly. After thorough mixing the china dish was removed from water bath and cooled. The coherent mass was then scrapped from the china dish and was passed through sieve no.60. The granules were then lubricated with Talc and Magnesium Stearate was added. The lubricated granules were passed through sieve no.100. The granules were compressed using a Single Punch Tablet Machine.

Evaluation of prepared granules (Pre compression parameters)

Angle of repose

Flow properties of the granules (before compression) were characterized in term of the angle of repose and the compressibility index. Static angle of repose was measured according to Fixed Funnel Method and Free Standing Cone method (Banker and Anderson, 1984)\(^8\) and the angle of repose was calculated using the equation: \[ \tan \theta = \frac{h}{r} \] where \( \tan \theta \) is Angle of Repose.

Bulk density

Loose Bulk Density (LBD) and Tapped Density (TBD) were determined for granules. LBD and TBD were calculated by using following formula. LBD = Wt of powder / Volume of powder. TBD = Wt of powder / Tapped volume of powder

Compressibility Index

Carr’s Compressibility Index for the prepared granules was determined by the equation
prescribed by Carr, (1965) as, Carr's Index (%) = TBD - LBD x 100

Evaluation of Tablet

Parameters at the time of compression of granules of selected drug was done was considered for Thickness as the size and shape of the tablet can be dimensionally described, monitored and controlled. A compressed tablet's shape and dimensions were determined by the tooling during the compression process. Hardness of the prepared tablets was accomplished to understand such term which means force required breaking a tablet in diametric compression test, which was determined by Monsanto Tester. The physical dimensions of the tablet along with the density of the material in the tablet formulation and their proportions were determined to notice the weight of the tablet. Diameter was fixed before compression of the tablet. Post compression parameters of the prepared Simvastatin tablets were done as soon as the tablets were prepared for weight variation by electronic balance as per the weight variation requirements and specifications. Friability test was considered as the loss due to abrasion and measured by Rouche Friabilater.

Drug content studies

The study to find out the actual drug content in different formulation against the standard drug was performed by taking the ratio of absorbance for the sample and the pure drug. Five tablets were taken and amount of drug present in each tablet was determined and the tablets were crushed in a Pestle mortar into powder which was transferred as amount equivalent to 40mg to 100ml standard flask. The power was dissolve in 5ml methanol and made up to volume with 0.1N HCl and the sample was mixed thoroughly and filtered through Whatman filter paper. The filtered solution was diluted suitably and analyzed for drug content by UV-VIS Spectrophotometer at wavelength 247nm and 257nm. Percentage of drug content was determined by comparing of standard with the prepared formulations.

In-vitro buoyancy study of prepared Simvastatin Tablets

In vitro buoyancy studies were performed for all the formulation as per the method describes by Rosa et al (1994). The randomly selected tablets from each formulation were kept in a 100ml beaker containing simulated gastric fluid pH 1.2 as per USP. The time was noted for the tablet to rise to the surface and there presence at the surface was considered as floating lag time. The overall floating time was calculated during the dissolution studies.

In vitro Dissolution studies

The In vitro Dissolution studies was done as one of the most important quality control test performed during the project period on pharmaceutical dosage forms and developed as a tool for predicting bioavailability in some cases, replacing clinical studies to determine bioequivalence. Study was carried out in 0.1N HCL using Dissolution Apparatus (Basket Type) as per IP specification. One tablet was placed inside the fine porous tube fitted with the motor and dissolution medium 0.1N HCL was poured in the rotated basket. A fraction of 5ml sample was collected at specific time interval than the same volume (5 ml) was replaced to maintain sink condition. Collected fractions of all the four formulations were scanned for drug content by using UV-VIS Spectrophotometer at 247nm and 257nm.

RESULTS AND DISCUSSION

During the study period, pre formulation study of selected drug Simvastatin was done first for physical observation, as the general appearance of the drug, its visual identity and overall 'elegance' is essential and it was found a white or almost white powder having slight drug smell and also found there is no leakage and crushing of the packet. The solubility of the pure drug was found maximum in Methanol followed by Ethanol then Chloroform. Acetone shows solubility by keeping the solution for short time. Melting point of the pure drug was found with a range between $135\, ^\circ\, C - 138\, ^\circ\, C$ and this range complies the UPS which shows the drug's purity specification. Partition coefficients were determined for getting the idea for estimating distribution of drugs within the body and to confirm the nature of the pure drug and that Partition coefficients was found to be 4.5. The loss on drying at $60\, ^\circ\, C$ to check the moisture content or the water molecules present in the drug which is necessary to confirm its stability and it was found that the loss
Table 1: Formulation of Simvastatin Tablets

<table>
<thead>
<tr>
<th>S. No.</th>
<th>Ingredients</th>
<th>F-1</th>
<th>F-2</th>
<th>F-3</th>
<th>F-4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Simvastatin</td>
<td>40mg</td>
<td>40mg</td>
<td>40mg</td>
<td>40mg</td>
</tr>
<tr>
<td>2</td>
<td>HPMCK4M</td>
<td>40mg</td>
<td>30mg</td>
<td>20mg</td>
<td>10mg</td>
</tr>
<tr>
<td>3</td>
<td>Ethyl cellulose</td>
<td>10mg</td>
<td>20mg</td>
<td>30mg</td>
<td>40mg</td>
</tr>
<tr>
<td>4</td>
<td>Sodium bicarbonate</td>
<td>30mg</td>
<td>30mg</td>
<td>30mg</td>
<td>30mg</td>
</tr>
<tr>
<td>5</td>
<td>Beeswax</td>
<td>40mg</td>
<td>40mg</td>
<td>40mg</td>
<td>40mg</td>
</tr>
<tr>
<td>6</td>
<td>Magnesium stearate</td>
<td>5mg</td>
<td>5mg</td>
<td>5mg</td>
<td>5mg</td>
</tr>
<tr>
<td>7</td>
<td>Talk</td>
<td>5mg</td>
<td>5mg</td>
<td>5mg</td>
<td>5mg</td>
</tr>
</tbody>
</table>

Table 2: Evaluation of granule properties of all prepared Simvastatin formulation

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Angle of Repose (θ)</th>
<th>LBD (g/ml)</th>
<th>TBD (g/ml)</th>
<th>Compressibility Index (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>33°.60'</td>
<td>0.467</td>
<td>0.555</td>
<td>15.85</td>
</tr>
<tr>
<td>F2</td>
<td>36°.99'</td>
<td>0.446</td>
<td>0.543</td>
<td>17.86</td>
</tr>
<tr>
<td>F3</td>
<td>34°.70'</td>
<td>0.476</td>
<td>0.588</td>
<td>19.04</td>
</tr>
<tr>
<td>F4</td>
<td>40°.20'</td>
<td>0.450</td>
<td>0.549</td>
<td>18.03</td>
</tr>
</tbody>
</table>

Table 3: Physico-chemical characteristics of the Simvastatin tablet during compression

<table>
<thead>
<tr>
<th>Formula</th>
<th>Thickness (mm)</th>
<th>Hardness (kg/cm²)</th>
<th>Diameter (mm)</th>
<th>Friability (%)</th>
<th>Weight variation (mg)</th>
<th>Drug content (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>3.1 ± 0.01</td>
<td>5.1</td>
<td>7</td>
<td>0.1259</td>
<td>156.93 - 182.37</td>
<td>97.97</td>
</tr>
<tr>
<td>F2</td>
<td>3.2 ±0.03</td>
<td>5.4</td>
<td>7</td>
<td>0.2557</td>
<td>161.17 - 189.29</td>
<td>98.64</td>
</tr>
<tr>
<td>F3</td>
<td>3.1 ± 0.02</td>
<td>6.0</td>
<td>7</td>
<td>0.2463</td>
<td>149.87 - 173.03</td>
<td>99.89</td>
</tr>
<tr>
<td>F4</td>
<td>2.9 ± 0.01</td>
<td>5.9</td>
<td>7</td>
<td>0.1215</td>
<td>153.45 - 178.27</td>
<td>99.10</td>
</tr>
</tbody>
</table>
The shape and dimensions of compressed tablets were determined by the type of tooling during the compression process. The shape of the tablets of all formulations remained circular with no visible cracks. The Thickness, Hardness and Diameter ranged from 2.9 ± 0.01 mm (F4) to 3.2 ± 0.03 mm (F2), 5.1 kg/cm² (F1) to 6.0 kg/cm² (F3) and 7 mm ((F1 - F4) respectively (Table-3).

The average percentage weight variation of 20 tablets which was performed in the study from each formulation remained within + 5 %. The percentage friability of all the four formulation remained within the range of 0.1215 % (F4) to 0.2557 % (F2). A maximum weight loss of not more than 1% of the weight of the tablets tested during the friability test was considered acceptable and any broken or smashed tablets were not picked up.

The drug content showed values in the range of 97.97 % (F1) to 99.89 % (F3) which reflects good uniformity in drug content among different formulations. The drug content was found as higher in Formula -3 (99.89 %) followed by Formula - 4 (99.10 %) then Formula - 2 (98.64 %) and Formula-1 (97.97 %), as expressed in Table- 3.

The time taken for the tablet to rise to the surface and float was taken as floating lag time which was found in a range of 15 second (F-1) to 29 seconds (F-4), and the overall floating time was calculated during the dissolution studies was found to be ranged between >5hrs (F-4) to >12hrs (F-1and F-2) under in vitro buoyancy studies (Table-4).

### Evaluation of Tablets

| Table 4: In Vitro Buoyancy and In Vitro Dissolution studies of formulations Simvastatin |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Formula       | F-1             | F-2             | F-3             | F-4             | Lag time (seconds) | Floating time (hrs) | Floating Fraction (hrs) | Floating Fraction (hrs) |
|               | 15.706          | 24.354          | 13.941          | 23.556          | >12hrs           | >12hrs          | >9hrs           | >5hrs           |
|                | 30.43           | 29.511          | 23.244          | 30.809          | >9hrs            | >9hrs           | >5hrs           | >5hrs           |
|                | 31.011          | 33.10           | 32.739          | 35.653          | >5hrs            | >5hrs           | >5hrs           | >5hrs           |
|                | 36.766          | 36.264          | 35.363          | 40.219          | >5hrs            | >5hrs           | >5hrs           | >5hrs           |
|                | 40.865          | 37.524          | 54.164          | 43.516          | >5hrs            | >5hrs           | >5hrs           | >5hrs           |

**In Vitro Dissolution studies**

The data obtained from *in vitro* dissolution studies for all the four formulations and it was noticed that tablets released 40.32 %, 43.80 %, 40.87 % and 47.77 % respectively at the end of 8 hrs (Table 16). The formulations were prepared mainly with HPMC K4M and Ethyl cellulose polymers varying in the amount and type of polymers HPMC K4M which was used in F-1 (40 mg), F-2 (30 mg), F-3 (20 mg), and F-4(10 mg) where as Ethyl cellulose polymer was used in F1-F-4 as 0 mg, 10 mg, 20 mg, and 30 mg respectively (Table-4). All the
formulations contained fixed or equal amount of
gas generating agent like sodium bicarbonate,
meltalbe material bees wax. Both polymers were
chosen as they are well established in the similar
studies and have great swelling and sustained
release properties respectively. Sodium
bicarbonate is added to the formulation as gas
generating agent. The formulation up on contact
with HCl liberates CO₂ and expels from the dosage
from creating pores through which water can
penetrate into dosage form and the rate of wetting
of polymer increases. The data obtained during
the study period are in full agreement with the
findings of Arun Kumar et al (2008)⁵ revealed the
proportions of polymer showed significant
difference in the release of drug.

ACKNOWLEDGEMENTS

Thanks are due to Prof. Pramod K. Verma,
Director General and Dr. S. Singh, Joint Director
Quality Assurance Laboratory, MPCST for extending
support and constant encouragement. The authors
are also thankful to all the staff of QAL offered
selfless support and assistance to perform
experimental work.

REFERENCES

1. Bodor, N. S. Chemical Aspects of Drug
Delivery Systems; Karsa, D. R., Stephenson,
R. A., Eds; Royal Society of Chemistry:
2. Controlled Drug Delivery: Challenges and
Strategies; Park, K., Ed.; American Chemical
3. Robinson, JR. Sustained and controlled
release drug delivery systems. Drugs and
Pharmaceutical Sciences Vol. 6. Marcel
4. Rathbone, MJ, Hadgraft J, Michael SR.
Modified-release drug delivery technology.
Drugs and the Pharmaceutical Sciences Vol.
Formulation and In Vitro evaluation of oral
floating tablets of atorvastatin calcium
of Oral Drug Delivery System using Floating
Microspheres., Drug Dev. Ind. Pharm, 1995,
21; 1725  3
7. Chien Y. W., Novel Drug Delivery Systems,
2nd edn., New York; Marcel Dekker Inc.,
1992; 4
In : The Theory and Practice of Industrial
Pharmacy. Lachman, L., Lieberman, H. A.
9. Carr R L., Evaluating flow properties of solids,
10. Rosa M, Zia H., Rhodes T. Dosing and testing
in vitro of a bioadhesive and floating drug
delivery system for oral application, Int. J